Genotyping was not performed for other CHEK2 variants besides 1100delC and there were too few carriers of PALB2 deleterious variants, a gene for which deleterious variants are known to be associated with development of CBC, to report.9 Additionally, HR status was determined in pathology departments of treating hospitals, not centrally using a standardized protocol. This evidence concerns the gene CHEK2 and complete blood cell count.